CASSIOPEA Study: Difference between revisions
Jump to navigation
Jump to search
(New page: {{CMG}} {{EJ}} Because idraparinux has a very long duration of action, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of the biotin moie...) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
Because idraparinux has a very long duration of action, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of the biotin moiety would allow the rapid removal of the drug upon the addition of avidin. A bioequipotency study of biotinylated idraparinux vs. idraparinux for the treatment of DVT is currently ongoing, and patients are being recruited into the phase III CASSIOPEA study of biotinylated idraparinux vs. warfarin for the treatment of PE. | Because idraparinux has a very long duration of action, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of the biotin moiety would allow the rapid removal of the drug upon the addition of avidin. A bioequipotency study of biotinylated idraparinux vs. idraparinux for the treatment of DVT is currently ongoing, and patients are being recruited into the phase III CASSIOPEA study of biotinylated idraparinux vs. warfarin for the treatment of PE. | ||
Latest revision as of 23:16, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Because idraparinux has a very long duration of action, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of the biotin moiety would allow the rapid removal of the drug upon the addition of avidin. A bioequipotency study of biotinylated idraparinux vs. idraparinux for the treatment of DVT is currently ongoing, and patients are being recruited into the phase III CASSIOPEA study of biotinylated idraparinux vs. warfarin for the treatment of PE.